Triple

T1143216
Position Surface form Disambiguated ID Type / Status
Subject European Medicines Agency E23502 entity
Predicate hasCommittee P1396 FINISHED
Object Pharmacovigilance Risk Assessment Committee
The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of human medicines and advising on risk management measures in the European Union.
E130558 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Pharmacovigilance Risk Assessment Committee | Statement: [European Medicines Agency, hasCommittee, Pharmacovigilance Risk Assessment Committee]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Pharmacovigilance Risk Assessment Committee
Context triple: [European Medicines Agency, hasCommittee, Pharmacovigilance Risk Assessment Committee]
  • A. Committee for Proprietary Medicinal Products
    The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
  • B. Committee for Medicinal Products for Veterinary Use
    The Committee for Medicinal Products for Veterinary Use is the European Medicines Agency’s scientific committee responsible for evaluating and providing opinions on veterinary medicines in the European Union.
  • C. Committee for Herbal Medicinal Products
    The Committee for Herbal Medicinal Products is a scientific body within the European Medicines Agency that evaluates and provides guidance on the safety and efficacy of herbal medicines in the European Union.
  • D. Committee for Orphan Medicinal Products
    The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
  • E. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
    The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a global body that develops and promotes unified scientific and technical standards to ensure the safety, quality, and efficacy of medicines worldwide.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Pharmacovigilance Risk Assessment Committee
Triple: [European Medicines Agency, hasCommittee, Pharmacovigilance Risk Assessment Committee]
Generated description
The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of human medicines and advising on risk management measures in the European Union.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Pharmacovigilance Risk Assessment Committee
Target entity description: The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of human medicines and advising on risk management measures in the European Union.
  • A. Committee for Proprietary Medicinal Products
    The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
  • B. Committee for Medicinal Products for Veterinary Use
    The Committee for Medicinal Products for Veterinary Use is the European Medicines Agency’s scientific committee responsible for evaluating and providing opinions on veterinary medicines in the European Union.
  • C. Committee for Herbal Medicinal Products
    The Committee for Herbal Medicinal Products is a scientific body within the European Medicines Agency that evaluates and provides guidance on the safety and efficacy of herbal medicines in the European Union.
  • D. Committee for Orphan Medicinal Products
    The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
  • E. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
    The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a global body that develops and promotes unified scientific and technical standards to ensure the safety, quality, and efficacy of medicines worldwide.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a493ef399c8190b04b9146d2314f59 completed March 1, 2026, 7:30 p.m.
NER Named-entity recognition batch_69a4bc4e93d48190b9fea886bf61aad7 completed March 1, 2026, 10:23 p.m.
NED1 Entity disambiguation (via context triple) batch_69ac59b2395c81909d4608bdaf1d57e8 completed March 7, 2026, 5 p.m.
NEDg Description generation batch_69ac5b52c43c8190b8972826a9a1ea5f completed March 7, 2026, 5:07 p.m.
NED2 Entity disambiguation (via description) batch_69ac5be4d9548190a0f1d57538f688c1 completed March 7, 2026, 5:09 p.m.
Created at: March 1, 2026, 7:44 p.m.